<DOC>
	<DOCNO>NCT01290757</DOCNO>
	<brief_summary>The objective Phase I trial demonstrate bioequivalence two capsule dabigatran etexilate make two different drug product batch . The reference batch dabigatran etexilate hard capsule 150 mg use currently approve capsule shell ( Qualicaps ) . The test batch dabigatran etexilate 150 mg hard capsule use new capsule shell ( Capsugel ) . The test batch drug product intend future commercial use .</brief_summary>
	<brief_title>Bioequivalence Two Different Capsule Types Dabigatran</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age =21 = 55 year 3 . Body Mass Index ( BMI ) =18.5 BMI = 29.9 kg/m^2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Clinically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Clinically relevant surgery gastrointestinal tract evidence significant gastrointestinal motility problem could affect absorption drug 3 . Diseases central nervous system ( include limit kind seizure , stroke psychiatric disorder ) within past 6 month 4 . Any history evidence blood dyscrasia , hemorrhagic diathesis , severe thrombocytopenia , cerebrovascular hemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition hemorrhagic tendencies 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy particular study drug excipients ) deem relevant trial judge investigator 8 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 9 . Alcohol abuse ( 20 g/day ) 10 . Drug abuse 11 . Any laboratory value outside reference range clinical relevance ( especially hemoglobin , thrombocyte , prothrombin time ( PT ) Activated Partial Thromboplastin Time ( Measure clot time ) ( aPTT ) positive drug virus screen 12 . Planned surgery within four week follow endof study examination 13 . Recent contemplate diagnostic therapeutic procedure potential uncontrollable bleeding within 14 day endof study examination</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>